Skip to content

DEROPHARMA: what changed

BE 1021.522.440NACE 47.730, Retail sale of pharmaceutical productsOther company

Position among the sector peers

What moved

Only one financial year

Comparing needs two financial years with figures read. This company has one.

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€60,071 to €80,447

Midpoint €68,561 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years earnings weight 50%

Adjusted equity €18,263
Capitalised earnings €101,879 to €142,630
Indication €60,071 to €80,447

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€18,263
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€18,263

Capitalised earnings

net result for the year (9904)
2025
€14,263
Average result
€14,263
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€101,879 / €118,858 / €142,630

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The value is an indication, not a valuation or advice. Prepared on 10 November 2026 via checked.be.